Fig. 1.

Flowchart of patient selection. Initially, there were 266 eligible patients. 108 patients were not enrolled, because they had not been proven to have fatty liver through imaging. Twenty patients with other causes of chronic hepatitis were also not enrolled. Patients who stopped pemafibrate for any reason and/or with a history of drinking and short duration of using pemafibrate were excluded from the study. Finally, 138 patients were enrolled for this study